Therapeutic role of EGFR - Tyrosine kinase inhibitors in non-small cell lung cancer with leptomeningeal metastasis
Leptomeningeal metastasis (LM) is a significant complication that advances fast and has a poor prognosis for patients with advanced non-small cell lung cancer (NSCLC) who have epidermal growth factor receptor (EGFR) mutations. Current therapies for LM are inconsistent and ineffective, and establishe...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-01-01
|
| Series: | Translational Oncology |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1936523323002188 |
| _version_ | 1797422666129342464 |
|---|---|
| author | Caiyan Jia Qian Xu Lu Zhao Fanming Kong Yingjie Jia |
| author_facet | Caiyan Jia Qian Xu Lu Zhao Fanming Kong Yingjie Jia |
| author_sort | Caiyan Jia |
| collection | DOAJ |
| description | Leptomeningeal metastasis (LM) is a significant complication that advances fast and has a poor prognosis for patients with advanced non-small cell lung cancer (NSCLC) who have epidermal growth factor receptor (EGFR) mutations. Current therapies for LM are inconsistent and ineffective, and established techniques such as radiation, chemotherapy, and surgery continue to fall short of potential outcomes. Nonetheless, EGFR tyrosine kinase inhibitors (TKIs) exhibit potent anti-tumor activity and hold considerable promise for NSCLC patients with EGFR mutations. Thus, assessing EGFR-TKIs effectiveness in treating these central nervous system (CNS) problems is crucial. This review integrates current literature on the intracranial efficacy of EGFR-TKIs to explore the varying impacts of approved EGFR-TKIs in LM patients and the therapeutic possibilities presented by other EGFR-TKIs in development. To delineate the optimal clinical treatment strategy, further exploration is needed regarding the optimal sequencing of EGFR-TKIs and the selection of alternative therapy options following initial treatment failure with EGFR-TKIs. |
| first_indexed | 2024-03-09T07:35:43Z |
| format | Article |
| id | doaj.art-d91cbe21c67245599042a48bcf1db0da |
| institution | Directory Open Access Journal |
| issn | 1936-5233 |
| language | English |
| last_indexed | 2024-03-09T07:35:43Z |
| publishDate | 2024-01-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Translational Oncology |
| spelling | doaj.art-d91cbe21c67245599042a48bcf1db0da2023-12-03T05:40:30ZengElsevierTranslational Oncology1936-52332024-01-0139101832Therapeutic role of EGFR - Tyrosine kinase inhibitors in non-small cell lung cancer with leptomeningeal metastasisCaiyan Jia0Qian Xu1Lu Zhao2Fanming Kong3Yingjie Jia4Department of Oncology, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, 300381, PR China; National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion, Tianjin, 300381, PR ChinaDepartment of Oncology, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, 300381, PR China; National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion, Tianjin, 300381, PR ChinaDepartment of Oncology, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, 300381, PR China; National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion, Tianjin, 300381, PR ChinaDepartment of Oncology, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, 300381, PR China; National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion, Tianjin, 300381, PR China; Corresponding authors at: Department of Oncology, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, 300381, PR China.Department of Oncology, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, 300381, PR China; National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion, Tianjin, 300381, PR China; Corresponding authors at: Department of Oncology, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, 300381, PR China.Leptomeningeal metastasis (LM) is a significant complication that advances fast and has a poor prognosis for patients with advanced non-small cell lung cancer (NSCLC) who have epidermal growth factor receptor (EGFR) mutations. Current therapies for LM are inconsistent and ineffective, and established techniques such as radiation, chemotherapy, and surgery continue to fall short of potential outcomes. Nonetheless, EGFR tyrosine kinase inhibitors (TKIs) exhibit potent anti-tumor activity and hold considerable promise for NSCLC patients with EGFR mutations. Thus, assessing EGFR-TKIs effectiveness in treating these central nervous system (CNS) problems is crucial. This review integrates current literature on the intracranial efficacy of EGFR-TKIs to explore the varying impacts of approved EGFR-TKIs in LM patients and the therapeutic possibilities presented by other EGFR-TKIs in development. To delineate the optimal clinical treatment strategy, further exploration is needed regarding the optimal sequencing of EGFR-TKIs and the selection of alternative therapy options following initial treatment failure with EGFR-TKIs.http://www.sciencedirect.com/science/article/pii/S1936523323002188Leptomeningeal metastasisEpidermal growth factor receptorEGFR tyrosine kinase inhibitorsNon-small cell lung cancerOsimertinib |
| spellingShingle | Caiyan Jia Qian Xu Lu Zhao Fanming Kong Yingjie Jia Therapeutic role of EGFR - Tyrosine kinase inhibitors in non-small cell lung cancer with leptomeningeal metastasis Translational Oncology Leptomeningeal metastasis Epidermal growth factor receptor EGFR tyrosine kinase inhibitors Non-small cell lung cancer Osimertinib |
| title | Therapeutic role of EGFR - Tyrosine kinase inhibitors in non-small cell lung cancer with leptomeningeal metastasis |
| title_full | Therapeutic role of EGFR - Tyrosine kinase inhibitors in non-small cell lung cancer with leptomeningeal metastasis |
| title_fullStr | Therapeutic role of EGFR - Tyrosine kinase inhibitors in non-small cell lung cancer with leptomeningeal metastasis |
| title_full_unstemmed | Therapeutic role of EGFR - Tyrosine kinase inhibitors in non-small cell lung cancer with leptomeningeal metastasis |
| title_short | Therapeutic role of EGFR - Tyrosine kinase inhibitors in non-small cell lung cancer with leptomeningeal metastasis |
| title_sort | therapeutic role of egfr tyrosine kinase inhibitors in non small cell lung cancer with leptomeningeal metastasis |
| topic | Leptomeningeal metastasis Epidermal growth factor receptor EGFR tyrosine kinase inhibitors Non-small cell lung cancer Osimertinib |
| url | http://www.sciencedirect.com/science/article/pii/S1936523323002188 |
| work_keys_str_mv | AT caiyanjia therapeuticroleofegfrtyrosinekinaseinhibitorsinnonsmallcelllungcancerwithleptomeningealmetastasis AT qianxu therapeuticroleofegfrtyrosinekinaseinhibitorsinnonsmallcelllungcancerwithleptomeningealmetastasis AT luzhao therapeuticroleofegfrtyrosinekinaseinhibitorsinnonsmallcelllungcancerwithleptomeningealmetastasis AT fanmingkong therapeuticroleofegfrtyrosinekinaseinhibitorsinnonsmallcelllungcancerwithleptomeningealmetastasis AT yingjiejia therapeuticroleofegfrtyrosinekinaseinhibitorsinnonsmallcelllungcancerwithleptomeningealmetastasis |